ECM
RPRX icon

Evergreen Capital Management’s Royalty Pharma RPRX Stock Holding History

Evergreen Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$804K Sell
14,344
-4,991
-26% -$260K 0.01% 639
2026
Q1 		$928K Hold
19,335
– – 0.02% 518
2025
Q4 		$747K Buy
19,335
+5,005
+35% +$191K 0.02% 554
2025
Q3 		$506K Buy
14,330
+83
+0.6% +$3K 0.01% 656
2025
Q2 		$513K Sell
14,247
-298
-2% -$9.87K 0.02% 544
2025
Q1 		$453K Sell
14,545
-93,112
-86% -$2.95M 0.02% 550
2024
Q4 		$2.75M Sell
107,657
-149,652
-58% -$3.97M 0.09% 211
2024
Q3 		$7.28M Sell
257,309
-41,008
-14% -$1.14M 0.24% 119
2024
Q2 		$7.87M Buy
298,317
+49,284
+20% +$1.37M 0.28% 101
2024
Q1 		$7.56M Buy
249,033
+6,532
+3% +$193K 0.29% 99
2023
Q4 		$6.81M Sell
242,501
-5,901
-2% -$162K 0.28% 104
2023
Q3 		$6.74M Sell
248,402
-634
-0.3% -$18.8K 0.3% 104
2023
Q2 		$7.66M Buy
249,036
+46,074
+23% +$1.56M 0.32% 94
2023
Q1 		$7.31M Buy
202,962
+97,025
+92% +$3.6M 0.33% 89
2022
Q4 		$4.19M Sell
105,937
-16
-0% -$668 0.2% 135
2022
Q3 		$4.26M Buy
105,953
+16
+0% +$683 0.22% 125
2022
Q2 		$4.45M Sell
105,937
-12,619
-11% -$517K 0.23% 122
2022
Q1 		$4.62M Buy
118,556
+33,852
+40% +$1.33M 0.19% 142
2021
Q4 		$3.38M Buy
+84,704
New +$3.29M 0.14% 180

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Evergreen Capital Management's RPRX Position: Q2 2026 in Review

Evergreen Capital Management reduced its Royalty Pharma (RPRX) stake by 26% in Q2 2026, selling an estimated $260K and leaving 14,344 shares worth $804K. The position accounts for 0.01% of the portfolio, ranked #639.

Evergreen Capital Management first reported a position in RPRX in Q4 2021 and has held it in 19 quarters since. The position peaked at $7.87M in Q2 2024. 641 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Evergreen Capital Management held 14,344 shares of Royalty Pharma worth $804K as of Q2 2026.
  • Evergreen Capital Management sold 4,991 Royalty Pharma shares in Q2 2026, an estimated $260K.
  • Royalty Pharma made up 0.01% of Evergreen Capital Management's portfolio in Q2 2026, its #639 holding.
  • Evergreen Capital Management first reported a position in Royalty Pharma in Q4 2021 and has held it in 19 quarters since.
  • Evergreen Capital Management's Royalty Pharma position peaked at $7.87M in Q2 2024.
  • 641 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Evergreen Capital Management's 13F filing for Q2 2026, filed 23 Jul 2026.